`
`IN THE UNITED STATES DISTRICT COURT
`FOR THE DISTRICT OF DELAWARE
`
`PURDUE PHARMA L.P.,
`PURDUE PHARMACEUTICALS L.P.,
`THE P.F. LABORATORIES, INC. and
`RHODES TECHNOLOGIES,
`
`Plaintiffs,
`
`v.
`
`ABHAI, LLC and KVK-TECH, INC.,
`
`Defendants.
`
`)
`)
`)
`)
`)
`) C.A. No. 17-450 (RGA)
`)
`)
`)
`)
`)
`
`CONSENT JUDGMENT
`BETWEEN
`PURDUE PHARMA L.P., THE P.F. LABORATORIES, INC.,
`PURDUE PHARMACEUTICALS L.P.,
`RHODES TECHNOLOGIES,
`AND ABHAI, LLC and KVK-TECH, INC.
`
`On consent of Purdue Pharma L.P., The P.F. Laboratories, Inc., Purdue
`
`Pharmaceuticals L.P. and Rhodes Technologies, and Abhai, LLC and KVK-Tech, Inc., and as
`
`settlement of this action between and among those parties, PURDUE PHARMA L.P., a limited
`
`partnership organized and existing under the laws of the State of Delaware, having a place of
`
`business at One Stamford Forum, 201 Tresser Boulevard, Stamford, Connecticut 0690 l, THE
`
`P.F. LABORATORIES, INC., a corporation organized and existing under the laws of the State
`
`of New Jersey, having a place of business at One Stamford Forum, 201 Tresser Boulevard,
`
`Stamford, Connecticut 06901, PURDUE PHARMACEUTICALS L.P., a limited partnership
`
`organized and existing under the laws of the State of Delaware, having a place of business at
`
`4701 Purdue Drive, Wilson, North Carolina 27893 and RHODES TECHNOLOGIES, a general
`
`partnership organized and existing under the laws of the State of Delaware, having a principal
`
`place of business at 498 Washington Street, Coventry, Rhode Island 02816 (collectively, the
`
`"Purdue Companies"), and ABHAI, LLC, a limited liability company organized and existing
`
`
`
`Case 1:17-cv-00450-RGA Document 12 Filed 12/28/17 Page 2 of 5 PageID #: 591
`
`under the laws of the State of Florida, having a place of business at 194 Inlet Drive, St.
`
`Augustine, FL 32080, and KVK-TECH, INC., a corporation organized and existing under the
`
`laws of the State of Pennsylvania, having a place of business at 110 Terry Drive, Suite 200,
`
`Newton, PA 18940 (collectively, the "Defendants") (the Plaintiffs and the Defendants being
`
`sometimes referred to herein individually as a "Party" and collectively as the "Parties"), it is
`
`Ordered, Adjudged and Decreed as follows:
`
`1.
`
`Terms used in this Consent Judgment and not otherwise defined shall have
`
`the meanings ascribed thereto in the Settlement Documents, dated as of December 22, 2017, by
`
`and among the Plaintiffs and the Defendants (the "Settlement Documents").
`
`U.S. Patent Nos. 9,492,389, 9,492,391, 9,492,392, 9,492,393 and 9,522,919
`
`(collectively, the "Specified Patents") are valid and enforceable with respect to any Oxycodone
`
`Products and any ANDA or 505(b)(2) Application for such products and, except for activities
`
`expressly permitted by the License granted pursuant to the Patent License Agreement, the
`
`Specified Patents are infringed by the Abhai ANDA and the Abhai Products.
`
`Unless otherwise expressly permitted pursuant to the terms of the Settlement
`
`Documents, the Defendants will not, prior to the Terminal Date, directly or indirectly, alone or in
`
`cooperation with any other person, make, have made, use, offer to sell, sell, import, market,
`
`distribute, participate in the profits of or indemnify others with respect to, any Oxycodone
`
`Product in the Territory.
`
`Except as provided for or may be agreed to in writing by the Plaintiffs and the
`
`Defendants in the Settlement Documents, from and after the Signing Date, the Defendants and
`
`their Associated Companies are enjoined from infringing the Specified Patents with respect to
`
`the Abhai ANDA and Abhai Products in the Territory.
`
`2
`
`
`
`Case 1:17-cv-00450-RGA Document 12 Filed 12/28/17 Page 3 of 5 PageID #: 592
`
`Civil Action No. 17-450 (the "Action"), including all claims and counterclaims, is
`
`hereby dismissed with prejudice. The Defendants waive any possible antitrust or other claims
`
`against the Plaintiffs based on conduct or events that have occurred prior to the Signing Date
`
`relating to the Abhai ANDA and the Abhai Products and the Specified Patents, as well as any
`
`claims or counterclaims that could have been pleaded in the Action.
`
`Except for the rights, agreements, covenants, waivers and releases specifically
`
`granted pursuant to the Settlement Documents, no other right, written or oral license or
`
`sublicense, covenant not to sue, waiver or release of future infringement or other written or oral
`
`authorization is or has been granted or implied by this Consent Judgment.
`
`Except as the Parties have heretofore expressly provided for in writing, by virtue
`
`of this Consent Judgment, all claims and demands for relief prayed for by the Plaintiffs and the
`
`Defendants in the Action are deemed to be satisfied.
`
`Subject to the provisions of the Settlement Documents, in addition to remedies for
`
`contempt of this Consent Judgment which the Plaintiffs or the Defendants, as the case may be,
`
`have, in the event of breach or violation by the other parties of the terms of this Consent
`
`Judgment, the non-breaching parties are entitled to appropriate injunctive relief against the
`
`breaching parties with respect to the breaching conduct solely upon a showing of a likelihood of
`
`success of establishing that such a breach occurred. The Parties agree that jurisdiction and venue
`
`for such an action exist in this District Court, and waive any and all defenses based on personal
`
`jurisdiction, subject matter jurisdiction and venue.
`
`This Consent Judgment is entered pursuant to Rule 58 of the Federal Rules of
`
`Civil Procedure, and the Action is hereby dismissed without costs or attorney's fees, save that
`
`this District Court shall retain jurisdiction over the Action, including, without limitation, over
`
`3
`
`
`
`Case 1:17-cv-00450-RGA Document 12 Filed 12/28/17 Page 4 of 5 PageID #: 593
`
`implementation of, or disputes arising out of, this Consent Judgment or the settlement of the
`
`Action. A prevailing party shall be entitled to recover attorney's fees in any such proceeding
`
`occurring after the entering of this Consent Judgment in which the case is found to be an
`
`exceptional one.
`
`Defendants may maintain or file Paragraph IV certifications
`
`in ANDA
`
`No. 207493 under 21 U.S.C. § 355U)(2)(A)(vii)(IV) (as amended or supplemented) consistent
`
`with the Settlement Documents.
`
`[remainder of this page intentionally left blank]
`
`4
`
`
`
`Case 1:17-cv-00450-RGA Document 12 Filed 12/28/17 Page 5 of 5 PageID #: 594
`
`MORRIS, NICHOLS, ARSHT & TUNNELL LLP
`
`KLEHR HARRISON HARVEY BRANZBURG LLP
`
`/s/ 1?,pdger <D. Smitfi II
`
`/s/ Saffy P.. o/egfite
`
`Jack B. Blumenfeld (#1014)
`Rodger D. Smith II (#3778)
`1201 North Market Street
`P.O. Box 1347
`Wilmington, DE 19899
`(302) 658-9200
`jblumenfeld@mnat.com
`rsmith@mnat.com
`
`David S. Eagle (#3387)
`Sally E. Veghte (#4762)
`919 N. Market Street
`Suite 1000
`Wilmington, DE 19801
`(302) 552-5508
`deagle@klehr.com
`sveghte@klehr.com
`
`Attorneys for Plaintiffs
`
`Attorneys for Defendants
`
`OF COUNSEL:
`
`OF COUNSEL:
`
`John J. Normile
`Pablo D. Hendler
`Kelsey I. Nix
`Gasper J. LaRosa
`Kenneth S. Canfield
`Sarah A. Geers
`Lisamarie LoGiudice
`JONES DAY
`250 Vesey Street
`New York, NY 10281-1047
`(212) 326-3777
`
`Jason G. Winchester
`JONES DAY
`77 West Wacker Drive
`Chicago, IL 60601
`
`Chad Landmon
`Edward M. Mathias
`Matthew S. Murphy
`AXINN, VEL TROP & HARKRIDER LLP
`90 State House Square
`Hartford, CT 06103
`(860) 275-8170
`
`Dan Feng Mei
`AXINN, VEL TROP &HARKRIDER LLP
`114 West 47th Street
`New York, NY 10036
`(212) 728-2200
`
`Attorneys for Plaintiffs Purdue Pharma L.P.,
`Purdue Pharmaceuticals L.P., The P.F.
`Laboratories, Inc., and Rhodes Technologies
`
`December 22, 2017
`
`SO ORDERED this l[' day o~, 2017.
`
`5
`
`